Get access to Hummingbird’s Mirna Biomarker Platform

Partnering

Enhanced clinical drug development

  • Disease & treatment monitoring marker
  • Immunological status
  • Toxicological & adverse event marker

Diagnostic development

  • Early diagnosis
  • Prognosis
  • Companion

Access to ip portfolio

  • Out-licensing
  • Co-development

Interested in collaboration?
Please contact us!

Get access to Hummingbird’s Mirna Biomarker Platform

IP

Dominant IP in whole blood

  • 29 patent families
  • Encompassing all major disease groups
  • Seventeen patents granted
  • Barrier to new entrants

Access to ip portfolio

  • Out-licensing
  • Co-development

Hummingbird’s contribution to grants

Grants

Validation of clinical biomarkers


Hummingbird is a premier and reliable partner with focus on discovery and validation of clinical biomarkers, including Quality assurance, RNA extraction, microRNA/mRNA Analysis, Bioinformatics

Hummingbird is currently partner in 3 European FP7-funded consortia:

  • BestAgeing
  • RiskyCAD
  • EURenOmics

Contact


Are you looking for a SME or Subcontractor as partner for your project proposal? Please contact us!


Contact